Cargando…

Non-small-cell lung cancer: how to manage RET-positive disease

Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1–2% of NSCLC, resulting in constitutive activation of downstream signalling pathways commonly involved in cell growth and su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andrini, Elisa, Mosca, Mirta, Galvani, Linda, Sperandi, Francesca, Ricciuti, Biagio, Metro, Giulio, Lamberti, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281974/ https://www.ncbi.nlm.nih.gov/pubmed/35912003 http://dx.doi.org/10.7573/dic.2022-1-5

Ejemplares similares

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease
por: Metro, Giulio, et al.
Publicado: (2022)

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
por: Ricciuti, Biagio, et al.
Publicado: (2022)

Non-small-cell lung cancer: how to manage EGFR-mutated disease
por: Pecci, Federica, et al.
Publicado: (2022)

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
por: Marinelli, Daniele, et al.
Publicado: (2022)

Advanced non-small-cell lung cancer: how to manage non-oncogene disease
por: De Giglio, Andrea, et al.
Publicado: (2022)

The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks
por: De Giglio, Andrea, et al.
Publicado: (2023)

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
por: Ricciuti, Biagio, et al.
Publicado: (2017)

Non-coding RNAs in lung cancer
por: Ricciuti, Biagio, et al.
Publicado: (2014)

Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer
por: Parisi, Claudia, et al.
Publicado: (2020)

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature
por: Baglivo, Sara, et al.
Publicado: (2020)

The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
por: Lamberti, Giuseppe, et al.
Publicado: (2020)

Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review
por: Zappi, Arianna, et al.
Publicado: (2023)

The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
por: Ke, Jun-yi, et al.
Publicado: (2023)

Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)
por: Lamberti, Giuseppe, et al.
Publicado: (2023)

Targeted therapy of RET fusion-positive non-small cell lung cancer
por: Shen, Zixiong, et al.
Publicado: (2022)

RET Inhibitors in Non-Small-Cell Lung Cancer
por: Cascetta, Priscilla, et al.
Publicado: (2021)

Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: a case report within the experience of a single institution
por: Di Federico, Alessandro, et al.
Publicado: (2021)

Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
por: Mendoza, Luis
Publicado: (2018)

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report
por: Metro, Giulio, et al.
Publicado: (2015)

Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
por: Gao, Ming, et al.
Publicado: (2023)

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape
por: Novello, Silvia, et al.
Publicado: (2023)

New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event
por: Lamberti, Giuseppe, et al.
Publicado: (2020)

An Update on Appendiceal Neuroendocrine Tumors
por: Andrini, Elisa, et al.
Publicado: (2023)

miRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance
por: Ricciuti, Biagio, et al.
Publicado: (2015)

Current management of RET rearranged non-small cell lung cancer
por: Stinchcombe, Thomas E
Publicado: (2020)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
por: Addeo, Alfredo, et al.
Publicado: (2018)

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation
por: Hayashi, Takuo, et al.
Publicado: (2021)

Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRAS(G12C)-Mutant Non–Small-Cell Lung Cancer
por: Lamberti, Giuseppe, et al.
Publicado: (2023)

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report
por: Meng, Yan, et al.
Publicado: (2022)

Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer
por: De Giglio, Andrea, et al.
Publicado: (2022)

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?
por: Metro, Giulio, et al.
Publicado: (2020)

Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases
por: Guo, Robin, et al.
Publicado: (2019)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
por: Takeda, Masayuki, et al.
Publicado: (2019)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges
por: Andrini, Elisa, et al.
Publicado: (2022)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
por: Paglialunga, Luca, et al.
Publicado: (2016)

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)
por: Takeuchi, Shinji, et al.
Publicado: (2021)

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
por: Subbiah, Vivek, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3155imvb991dmecha85lgebp40